CJC-1295 (without DAC) vs MOTS-c
Well Studied vs Well Studied
synergistic Mechanism-based · 51% CJC-1295 (without DAC) helps counteract the insulin-disrupting effects of MOTS-c. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
CJC-1295 (without DAC) MOTS-c
Weight 3,367.97 Da 2,174.6 Da
Half-life 30 minutes - 2 hours ~30 minutes
Chain 30 amino acids 16 amino acids
Type GHRH analog Mitochondrial-derived peptide (MDP)
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
MOTS-c
01 Enhanced insulin sensitivity (~30% improvement)
02 Improved glucose metabolism and tolerance
03 AMPK pathway activation
04 Mitochondrial function optimization
05 Exercise performance enhancement (12-15% improvement)
06 Potential lifespan extension (6.4% median increase in mice)
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
MOTS-c
Start 5mg daily, increase to 10-15mg based on goals / Daily for metabolic support, or 3x weekly for anti-aging
Metabolic health 5-10mg Once daily
Anti-aging protocol 15mg 3x weekly
Exercise performance 10-15mg Pre-workout
Conservative start 5mg Once daily
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
MOTS-c
Generally well-tolerated in animal studies with minimal side effects
Mild injection site reactions (redness, swelling)
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Pregnancy or breastfeeding
WADA prohibited substance (banned for athletic competition)
Limited long-term human safety data
Research Evidence
CJC-1295 (without DAC) MOTS-c
Status Well Studied Well Studied
References 5 studies 5 studies
Latest November 2024 August 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.